Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioRBC vs 51Cr-labeled RBCs for Autologous Transfusion Recovery and Survival
NCT07446647Phase 1Recruiting
- Sponsor
- Jose A. Cancelas
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Biotinylated red blood cell (2 arms), sponsored by Jose A. Cancelas. Primary endpoints: 24-hour Post-transfusion Recovery at Day 43 and Lifespan of Red Blood Cells at Day 154. Started Apr 2026; status: recruiting.
02
Drugs
Biotinylated red blood cell
Beyond the preview
Go deeper on NCT07446647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446647.